CLAIMS

1. Use of a lysine acetyltransferase 6 (KAT6) inhibitor having the structure



, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating cancer in a subject, wherein the subject is to be administered a daily dose of from about 0.1 mg to about 15 mg of the lysine acetyltransferase 6 (KAT6) inhibitor, or a pharmaceutically acceptable salt thereof.

2. Use of 2-methoxy-*N*-{4-methoxy-6-[(1*H*-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating cancer in a subject, wherein the subject is to be administered a daily dose of from about 0.1 mg to about 15 mg of 2-methoxy-*N*-{4-methoxy-6-[(1*H*-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide, or a pharmaceutically acceptable salt thereof, and wherein the medicament is to be administered in combination with

    a) an amount of a cyclin-dependent kinase 4 (CDK4) inhibitor;

    b) an amount of an antiestrogen; or

    c) an amount of a CDK4 inhibitor and an amount of an antiestrogen.

3. The use of claim 1 or claim 2, wherein the daily dose of the 2-methoxy-*N*-{4-methoxy-6-[(1*H*-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide, or a pharmaceutically acceptable salt thereof, is to be administered once per day (QD).

4. The use of any one of claims 1 to 3, wherein the 2-methoxy-*N*-{4-methoxy-6-[(1*H*-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide, or a pharmaceutically acceptable salt thereof, is to be administered in an amount of from about 0.5 mg to about 5 mg QD.

5. The use of claim 4, wherein the 2-methoxy-*N*-{4-methoxy-6-[(1*H*-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide, or a pharmaceutically acceptable salt thereof, is to be administered in an amount of about 0.5 mg QD.

6. The use of claim 4, wherein the 2-methoxy-*N*-{4-methoxy-6-[(1*H*-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide, or a pharmaceutically acceptable salt thereof, is to be administered in an amount of about 1 mg QD.

7. The use of claim 4, wherein the 2-methoxy-*N*-{4-methoxy-6-[(1*H*-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide, or a pharmaceutically acceptable salt thereof, is to be administered in an amount of about 2 mg QD.

8. The use of claim 4, wherein the 2-methoxy-*N*-{4-methoxy-6-[(1*H*-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide, or a pharmaceutically acceptable salt thereof, is to be administered in an amount of about 3 mg QD.

9. The use of claim 4, wherein the 2-methoxy-*N*-{4-methoxy-6-[(1*H*-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide, or a pharmaceutically acceptable salt thereof, is to be administered in an amount of about 4 mg QD.

10. The use of claim 4, wherein the 2-methoxy-*N*-{4-methoxy-6-[(1*H*-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide, or a pharmaceutically acceptable salt thereof, is to be administered in an amount of about 5 mg QD.

11. The use of any one of claims 1-10, wherein the 2-methoxy-*N*-{4-methoxy-6-[(1*H*-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide, or a pharmaceutically acceptable salt thereof, is to be administered orally.

12. The use of any one of claims 2-11, wherein the CDK4 inhibitor is a CDK4 selective inhibitor or a CDK4/6 inhibitor.

13. The use of claim 12, wherein the CDK4 inhibitor is a CDK4 selective inhibitor.

14. The use of claim 13, wherein the CDK4 selective inhibitor is 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1*H*-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-*threo*-pentitol, or a pharmaceutically acceptable salt thereof.

15. The use of claim 12, wherein the CDK4 inhibitor is a CDK4/6 inhibitor.

16. The use of claim 15, wherein the CDK4/6 inhibitor is abemaciclib, ribociclib or palbociclib, or a pharmaceutically acceptable salt thereof.

17. The use of any one of claims 2-16, wherein the antiestrogen is an aromatase inhibitor, a selective estrogen receptor degrader (SERD) or a selective estrogen receptor modulator (SERM).

18. The use of claim 17, wherein the antiestrogen is fulvestrant.

19. The use of claim 17, wherein the antiestrogen is letrozole.

20. The use of any one of claims 1-19, wherein the cancer is breast cancer, lung cancer, or prostate cancer.

21. The use of claim 20, wherein the cancer is breast cancer.

22. The use of claim 21, wherein the breast cancer is ER+ HER2- breast cancer.

23. The use of any one of claims 1-22, wherein the subject is a human.